*Corresponding Author: suhas.siddheshwar@pravara.in 33 DOI: https://doi.org/10.52756/ijerr.2024.v42.003 Int. J. Exp. Res. Rev., Vol. 42: 33-39 (2024) RP-HPLC Method Development and Validation for Estimation of Ticagrelor in Bulk and Pharmaceutical Dosage Form Suhas S. Siddheshwar*, Ajay R. Borhade, Someshwar D. Mankar, Santosh B. Dighe and Arshu P. Patel Department of Quality Assurance Technique, Pravara Rural College of Pharmacy, Pravaranagar, Tal-Rahata, Ahmednagar-413736, Maharashtra, India E-mail/Orcid Id: SSS, suhas.siddheshwar@pravara.in, https://orcid.org/0000-0002-7944-9470; AB, ajayborhade10@gmail.com, https://orcid.org/0009-0005-9078- 8114; SDM, sdmankar655@gmail.com, https://orcid.org/0000-0003-3991-9412; SBD, santosh.dighe@pravara.in, https://orcid.org/0000-0003-3260- 2981; APP, arshupatel59@gmail.com, https://orcid.org/0000-0002-3941-9453 Introduction Ticagrelor belongs to the Category Anti-Platelet Agent. Ticagrelor is a P2Y12 receptor antagonist (Tao L et al., 2022). The IUPAC name is (1S,2S,3R,5S)-3-(7- {[(1R,2S)-2-(3,4- difluorophenyl)cyclopropyl]amino}-5- (propylsulfanyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3- yl)-5-(2- hydroxyethoxy)cyclopentane-1,2-diol (Kumar et al., 2016). Ticagrelor is a P2Y12 receptor antagonist (Nikitha and Ajitha, 2016). Literature survey revealed estimation of Ticagrelor by several techniques, such as Stability-Indicating RP-HPLC Method for the Determination Ticagrelor in Pharmaceutical Dosage Form (Patel and Patel, 2014; Parida et al., 2018; Pappula et al., 2021). The RPHPLC method was developed and validated to estimate Ticagrelor in Bulk and The Pharmaceutical Tablet (Meena et al., 2021; Mankar et al., 2023; Patil and Godge, 2024). The Formulations and stability are indicating the UPLC method and the the estimation of ticagrelor in bulk and its tablet are used in dosage form (Kulkarni and Gajare, 2016; Omaima et al., 2019; Sri Ranjani et al., 2021; Deshpande et al., 2023; Farooq and Khan, 2023; Gosavi et al., 2023). The quantitative determination of Ticagrelor in pharmaceutical dosage forms was done using the Ultra Article History: Received: 12 th Sep., 2023 Accepted: 28 th Jul., 2024 Published: 30 th Arg., 2024 Abstract: Ticagrelor is a selective Adenosine diphosphate (ADP)-receptor antagonist which is prescribed in the form of tablets and acts as an oral antiplatelet for the prevention of further thrombotic events in patients with Acute coronary syndrome (ACS) and those undergoing Percutaneous coronary intervention (PCI). Therefore, accurate and reliable determination of Ticagrelor in bulk and in dosage forms is vital for clinical consideration. The objective of the method is to develop a new, simple, sensitive, accurate, and economical analytical method for the determination of assay of Ticagrelor Tablet and to perform a forced degradation study of Ticagrelor Tablet by RP- HPLC. Chromatographic separation was achieved on an UHPLC equipped with reverse phase C-18 (250 × 4.6mm, 5μ) with a mobile phase composed of acetonitrile and buffer solution (75:25) at a flow rate of 1.10 ml/min. The effluents were detected at a wavelength of 256 nm. The retention time of Ticagrelor was found to be at 3.579 min. The correlation coefficient for Ticagrelor was found to be 0.997. Recovery of Ticagrelor in the formulation was found to be 98%-102%. LOD and LOQ values of Ticagrelor were found to be 1.31 and 3.98, respectively. The method was proven to be precise (%RSD=2%), accurate (>90%), and specific for the measurement of Ticagrelor in tablets. Thus, being simple, accurate, precise, and rapid, the newly developed RP- HPLC method is recommended for the estimation of Ticagrelor in nature. Due to its high sensitivity and specificity, it is a suitable choice for identifying Ticagrelor in drugs and other products and differentiating hid similarities. However, this method can effectively be used for routine assay and stability study, which can help manage cardiovascular diseases since the quality and efficacy of Ticagrelor-containing products are significant to patients’ condition. Keywords: RP-HPLC, Tablet dosage form, Ticagrelor, Validation How to cite this Article: Suhas S. Siddheshwar, Ajay R. Borhade, Someshwar D. Mankar, Santosh B. Dighe and Arshu P. Patel (2024). RP-HPLC Method Development and Validation for Estimation of Ticagrelor in Bulk and Pharmaceutical Dosage Form. International Journal of Experimental Research and Review, 42, 33-39. DOI: https://doi.org/10.52756/ijerr.2024.v42.003